Assessment of salvage regimens post CAR-T cell therapy for patients with diffuse large B-cell lymphoma

According to data from a retrospective analysis of DLBCL patients with progressive disease after receiving anti-CD19 CAR T-cell therapy, those who responded to CAR19 therapy have significantly better median overall survival with salvage therapy (i.e., lenalidomide, Bruton tyrosine kinase inhibitor, checkpoint inhibitor, chemo-immunotherapy, allogeneic transplant, and other) compared with CAR19 non-responders (not reached vs. 10.9 months, respectively; P = .0187).